• Strategic Collaboration underscores Nestlé Health Science’s commitment to innovation in the management of food allergies and building a broad portfolio of solutions addressing the medical need of patients
• Aimmune is developing treatments for life-threatening food allergies; lead product AR101 is in Phase III for peanut allergy with US FDA Breakthrough Therapy Designation

Epalinges, Switzerland, 4 November 2016 – Nestlé Health Science announced today that it will make an equity investment of USD 145 million in US-based Aimmune Therapeutics (Nasdaq:AIMT), which corresponds to a 15% stake after completion of the transaction. The parties also entered into a strategic collaboration to accelerate the development of innovative oral immunotherapy biologics designed to desensitize people with food allergies and protect them from the consequences of accidental exposure.